- Research Article
- 10.1016/j.ekir.2026.104816
WCN26-5306 KIDNEY HIERARCHICAL COMPOSITE ENDPOINT IN JAPANESE PARTICIPANTS: A POST-HOC SUBGROUP ANALYSIS FROM THE DAPA-CKD TRIAL
- Apr 01, 2026
- Kidney International Reports
- Dustin J Little + 12 more +12
Publications from 2021 to 2026
Showing 10 of 1,813 papers
WCN26-5306 KIDNEY HIERARCHICAL COMPOSITE ENDPOINT IN JAPANESE PARTICIPANTS: A POST-HOC SUBGROUP ANALYSIS FROM THE DAPA-CKD TRIAL
Efficacy and safety of as-needed albuterol-budesonide versus albuterol in patients with asthma aged 12 to <18 years: design of the randomised, double-blind, parallel-group phase IIIb ACADIA trial.
Asthma among adolescents (aged 12-<18 years) is a common condition with high disease burden. Many are undertreated, at risk of adverse outcomes and exhibit poor adherence to maintenance medication. As-needed albuterol-budesonide 180/160 µg reduced the risk of severe exacerbations by 27% compared with as-needed albuterol 180 µg in patients aged ≥12 years, with moderate-to-severe asthma receiving inhaled corticosteroid (ICS) maintenance therapy in the MANDALA trial. A small number of adolescents were included in MANDALA, but data were inconclusive. The randomised, double-blind, multicentre, phase IIIb ACADIA trial is evaluating as-needed albuterol-budesonide versus as-needed albuterol in adolescents with asthma. A planned 440 adolescents (aged 12-<18 years) with asthma using as-needed albuterol with low- to high-dose ICS-containing maintenance medications (with or without other controllers) and who had ≥1 severe exacerbation in the previous 12 months are randomised to as-needed albuterol-budesonide 180/160 µg or as-needed albuterol 180 µg for 52 weeks while continuing their own maintenance therapy. The primary endpoint is the annualised rate of severe asthma exacerbations. Secondary endpoints are the time to first severe asthma exacerbation and annualised total systemic corticosteroid exposure for asthma per participant. To minimise the number of adolescents exposed to study medications, the treatment effect will be estimated by partially extrapolating results from the patient population in the MANDALA trial using a Bayesian dynamic borrowing approach. Ethical approval was obtained from the investigators' institutional review boards. Enrolment began in May 2024. Results will be presented at respiratory congresses and published in peer-reviewed journals. NCT06307665.
Read moreDifference in Exposure and Tolerability when Comparing Intratracheal Instillation with Inhaled Delivery.
To investigate the impact of two different routes of administration on the lung and systemic exposure of drugs designed for local delivery to the lung. In our comparative studies, similar lung doses of three different drugs were administered to rodents by both intratracheal instillation and inhaled delivery. An obvious but unexpected difference in the exposure was observed. Immediately after the dose, the initial plasma concentration was much higher whereas the initial fraction of the lung dose in the lung was clearly lower for the instillation compared with the inhaled delivery. There was also a difference in the tolerability for one of the drugs when the same lung dose was administered and the inhaled dose was, in contrast to the instilled dose, tolerated by the mice. A plausible explanation for the observed but contrary to expected difference is that the drugs leaked from the lung into the systemic circulation already during the instillation procedure due to its invasive nature.
Read moreAbstract DP282: CTA Spot Sign and Response to Andexanet in FXai-associated Intracerebral Hemorrhage: a Secondary Analysis of ANNEXa-I
Introduction: The spot sign identified on CT angiography (CTA), is a well-established predictor of hematoma expansion (HE), but its role in FXai-related intracerebral hemorrhage (ICH) remains poorly explored. We investigated the association between spot sign and HE in patients with acute FXai-associated ICH and to assess whether its presence modified the treatment effect of andexanet alfa. Methods: Participants with a qualifying ICH on baseline brain imaging and available CTA at baseline were included in this post-hoc analysis of the ANNEXa-I trial. Imaging analyses assessed the presence of spot sign and its features (e.g., number, maximum diameter, maximum density, co-localization with hypodensity). HE was defined as a hematoma volume increase of ≥12.5 mL or ≥35% between baseline and 12 hours after randomization. The association between spot sign presence and its characteristics with HE was assessed with logistic regression analysis adjusted for time from symptom onset to scan, baseline hematoma volume, and diastolic blood pressure. The treatment effect modification of andexanet on HE by these imaging variables was assessed with a multivariable regression analysis. Results: Of the 530 patients in the intention-to-treat population, 156 had CTA performed and were included in this study (66 [42.3%] female, mean [ + SD] age 78.5 [±7.8]) ( Table 1 ). HE was observed in 55 (35.7%) patients and 31 (20.1%) patients had a spot sign. Spot sign presence (adjusted odds ratio [aOR] 4.24 [95% CI=1.55-11.56]), as well as some of its features, such as diameter >5 mm (aOR 5.40 [95% CI=1.39-20.97]), central location (aOR 7.76 [95%CI=1.63-37.03]), and co-localization with a hypodensity (aOR 6.56, [95%CI=1.46-29.50]) were associated with HE following multivariable adjustment ( Table 2 ). HE occurred in 36 (29.3%) patients with no spot sign (andexanet 20% vs. usual care 38.1%; NNT with andexanet to prevent HE: 5.6) and in 19 (61.3%) with a spot sign (andexanet 45% vs. usual care 90.9%; NNT with andexanet to prevent HE: 2.2). No significant heterogeneity in the proportional reduction of HE with andexanet was observed based on spot sign presence (p-interaction=0.150) or its characteristics ( Figure 1 ). Conclusions: The presence of the spot sign and its features were significantly associated with HE in FXai-associated ICH. The treatment effect of andexanet was still consistent regardless of the presence of the spot sign and its features
Read moreEngineering Saccharomyces cerevisiae to improve heterologous abscisic acid production
Sex-specific associations between surgery-induced weight loss and cancer outcomes: A post hoc analysis of the prospective, controlled Swedish Obese Subjects study.
Obesity increases cancer risk, whereas surgery-induced weight loss is associated with reduced risk. Risk-based patient stratification may be needed to better understand and maximize benefits of weight loss interventions in individuals with obesity. To this end, comprehensive data from high-quality studies with extended follow-up are imperative. This study examines the link between bariatric surgery and long-term cancer outcomes, focusing on patient subgroups defined by previously suggested predictors of treatment benefit, such as sex and baseline insulin levels. This post-hoc analysis used data from the Swedish Obese Subjects (SOS) study, a prospective, controlled intervention trial, designed to investigate the long-term effects of bariatric surgery-induced weight loss (ClinicalTrials.gov, NCT01479452). The study was conducted at 25 public surgical departments and 480 primary healthcare centers across Sweden. Between Sept 1, 1987, and Jan 31, 2001, 2,007 per-protocol patients with obesity who underwent bariatric surgery (gastric bypass, n = 266; gastric banding, n = 376; vertical banded gastroplasty, n = 1,365) and 2,040 matched controls, receiving standard nonsurgical obesity-related care, were recruited. Inclusion criteria were age 37-60 years and a body mass index (BMI) ≥34 kg/m2 for men and ≥38 kg/m2 for women. The primary outcome measures were cancer events and cancer-related deaths, captured through nearly complete data sourced from national Swedish health registries. Female-specific cancers were defined as gynecologic and breast cancers. Analyses were adjusted (adj) for baseline age, sagittal diameter, alcohol consumption, smoking, and serum insulin levels. The study was closed on December 31, 2022. Median follow-up was 26.8 years (interquartile range (IQR) [22.9, 29.6]) in the surgery group and 24.9 years (IQR [18.7, 28.8]) in the control group. Bariatric surgery was associated with a lower overall cancer incidence rate in women (adjusted hazard ratio (HRadj) = 0.78; 95% confidence interval (CI) [0.67, 0.90]; p = 0.001), but not in men (sex-treatment interaction p = 0.013). The HRadj for overall cancer mortality rate in women was 0.78 (95% CI [0.61, 1.00]; p = 0.050). In women, surgery was associated with a lower incidence rate of both obesity-related cancers (HRadj = 0.70; 95% CI [0.58, 0.85]; p < 0.001) and female-specific cancers (HRadj = 0.60; 95% CI [0.47, 0.75]; p < 0.001). Importantly, subgroup analyses showed that the associations between surgery and female-specific cancer incidence, as well as female-specific cancer-related mortality, were stronger in women with high baseline insulin levels (insulin-treatment interaction p = 0.021 and 0.039, respectively). The main limitation is that cancer was not a predefined study outcome. Bariatric surgery is associated with a lower risk of cancer and cancer-related mortality in women with obesity, with the strongest association observed for female-specific cancers in women with elevated baseline insulin levels. In men, bariatric surgery was not associated with overall cancer incidence or mortality. These findings support incorporating risk-based stratification to better tailor cancer prevention strategies in obesity care.
Read moreOxabispidine-derived ionizable lipids for effective mRNA delivery to the lungs using lipid nanoparticles.
Lipid nanoparticles have been proven effective for mRNA delivery to the liver and in a vaccine context. There is general interest in identifying new ionizable lipids to enable safe and efficient mRNA delivery to a wider range of tissues and cells. A new series of ionizable lipids was developed using a conformationally constrained bicyclic diamine oxabispidine head group that shifts the apparent pKa of nanoparticles to higher values relative to those reported as optimal for liver and vaccine delivery. By optimizing the lipid tail structure, we identified a lead lipid that efficiently encapsulated mRNA using the standard 4-component LNP formulation and showed potent and safe local delivery to the lungs in rats via the inhalation and intratracheal routes.
Read moreEnhancing molecular structure elucidation with reasoning-capable LLMs
We introduce a novel workflow that integrates reasoning-capable language models (LLMs) with chemical analysis tools to enhance molecular structure determination using NMR spectroscopy.
Read moreComorbidities and mortality in subgroups of adults with diabetes with up to 14 years follow-up: a prospective cohort study in Sweden.
A review of the state-of-the-art: progress in ultrasonic and acoustic techniques for quality assessment in the development and manufacturing of oral solid dosage forms - Part I: theoretical foundations and principles.